Investors Alert: Zynex Securities Class Action and April Lead Plaintiff Deadline

Overview of the Zynex Class Action Lawsuit

In a significant legal development, national shareholder rights law firm Hagens Berman has brought to light a securities class action lawsuit against the former executives of Zynex, Inc. This legal move comes in the wake of serious allegations of systematic overbilling and a fraudulent revenue reporting scheme involving excessively shipping medical supplies to patients who did not require them.

The lawsuit, titled Beidel v. Thomas Sandgaard, et al. and filed in the U.S. District Court for the District of Colorado, seeks to recover losses for investors who purchased Zynex securities between February 25, 2021, and December 15, 2025. This case highlights a critical moment for investors, especially as they approach a key deadline of April 21, 2026, for filing as Lead Plaintiff in this class action.

Allegations Against Zynex

The backbone of the lawsuit is the assertion that Zynex misled its investors through dishonest reporting of business growth, which the lawsuit terms as "record growth." However, this was alleged to be artificially inflated through a scheme of oversupplying medical supplies — particularly electrode pairs — well above what was medically necessary. The complaint emphasizes this practice not only deceived investors but also led to an alarming situation where Zynex faced serious legal ramifications involving the Tricare military health program.

Systematic Overbilling Practices

According to the complaint, it is alleged that Zynex engaged in systematic overbilling by delivering up to 128 electrode pairs per month to individual patients, which is highly excessive and not clinically warranted. This unscrupulous tactic was reportedly employed to inflate billing rates for both government programs and private insurers. The grave implications of this included Tricare suspending substantial revenue payment streams, which accounted for around 25% of Zynex's income.

Legal Consequences and Bankruptcy

In a devastating twist, revelations regarding these fraudulent activities led to the indictment of former CEO Thomas Sandgaard and former COO Anna Lucsok for securities and healthcare fraud. These indictments precipitated immediate removal from their positions, while Zynex followed suit by filing for Chapter 11 bankruptcy. The stock, which traded under the symbol ZYXI before being suspended on December 24, 2025, has since been allowed to trade under ZYXIQ, albeit at significantly diminished values.

Critical Steps for Investors

For those who invested in Zynex during the class period, contacting Hagens Berman is crucial to discussing potential claims. The firm is encouraging investors who experienced significant losses to act before the approaching April 21, 2026, deadline, which is when investors can apply to be a Lead Plaintiff. For more detailed information, investors can visit the Hagens Berman Zynex case page to access a copy of the complaint as well as gain insight into the next steps in this ongoing legal battle.

Protecting the Rights of Whistleblowers

Moreover, Hagens Berman's investigative team strongly advocates for whistleblowers who possess non-public knowledge related to Zynex's practices. Those individuals are urged to consider their options for supporting the investigation while also exploring the SEC Whistleblower program, which offers rewards for invaluable information leading to successful recovery efforts.

In summary, as Zynex faces allegations that threaten its integrity and financial standing, affected investors must take immediate action to safeguard their interests. Engaging with experienced legal counsel is imperative for navigating the complexities surrounding these developments and ensuring they have a voice and a chance for recovery amidst the unfolding drama of corporate misconduct.